Christoph Uleer Sign in to save

ORCID 0000-0002-7937-8182 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (6)

2× Praxisgemeinschaft Frauenärzte am Bahnhofsplatz, Hildesheim
2× Facharzt für Frauenheilkunde und Geburtshilfe, Hildesheim, Germany
2× Praxisgemeinschaft Frauenärzte am Bahnhofsplatz, Hildesheim, Germany
1× 16Gynecologists at Bahnhofsplatz, Hildesheim, Germany
1× 10Gemeinschaftspraxis Hildesheim, Hildesheim, Germany
1× Practice of Gynecology and Oncology, Hildesheim, NDS, Germany

Papers 9 stored

All · Aachen affiliation only

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial
2024 Clinical Cancer Research article Medicine PARP inhibition in cancer therapy

6

citations
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures
2023 Geburtshilfe und Frauenheilkunde article Medicine Endometrial and Cervical Cancer Treatments Open access

21

citations
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) – Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care
2023 Geburtshilfe und Frauenheilkunde article Medicine Endometrial and Cervical Cancer Treatments Open access

6

citations
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
2022 The Lancet Oncology article Medicine HER2/EGFR in Cancer Research

93

citations
Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker
2022 Senologie - Zeitschrift für Mammadiagnostik und -therapie article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

0

citations
Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien
2021 Senologie - Zeitschrift für Mammadiagnostik und -therapie article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

0

citations
Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
2021 Geburtshilfe und Frauenheilkunde article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

14

citations
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
2021 Geburtshilfe und Frauenheilkunde article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

7

citations
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial
2021 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies

12

citations

9 results

Christoph Uleer ▲ Sign in to save

Departments & institutes in Aachen

Papers 9 stored

Christoph Uleer Sign in to save